AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-08. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
== Further reading == A System of Blood Analysis by Folin and Wu (1919) On the determination of creatinine and creatine in urine by Otto Folin (1914) Recommendations for Improving Serum Creatinine Measurement: A Report from the Laboratory Working Group of the National Kidney Disease Education Program by Gary L. Myers et al. (2006) "Max Jaffé (1841–1911)". Nature. 148 (3743): 110. 1941. Bibcode:1941Natur.148T.110.. doi:10.1038/148110d0.
==== 700–799 ==== Register of County Court Judgments (Amendment) Regulations 1993 (S.I. 1993/710) County Court (Amendment) Rules 1993 (S.I. 1993/711) County Court (Forms)(Amendment) Rules 1993 (S.I. 1993/712) North Staffordshire Hospital Centre National Health Service Trust (Change of Name) Order 1993 (S.I. 1993/713) Housing Renovation etc. Grants (Prescribed Forms and Particulars) (Welsh Forms and Particulars) (Amendment) Regulations 1993 (S.I. 1993/715) Combined Probation Areas (Amendment) (No. 2) Order 1993 (S.I. 1993/716) A4 and A46 Trunk Roads (Batheaston/Swainswick Bypass and Slip Roads) Order 1993 (S.I. 1993/717) A4 and A46 Trunk Roads (Batheaston/Swainswick Bypass and Slip Roads) (Detrunking) Order 1993 (S.I. 1993/718) Export of Goods (Control) (Bosnia-Herzegovina) (ECSC) Order 1993 (S.I. 1993/719) Police (Common Police Services) (Scotland) Order 1993 (S.I. 1993/720) Grant for Bail Services (Scotland) Order 1993 (S.I. 1993/721) Social Security (Industrial Injuries) (Dependency) (Permitted Earnings Limits) Order 1993 (S.I. 1993/722) Social Security Benefits Up-rating Regulations 1993 (S.I. 1993/723) Income Tax (Sub-contractors in the Construction Industry) (Amendment) Regulations 1993 (S.I. 1993/724) Income Tax (Employments) (No. 24) Regulations 1993 (S.I. 1993/725) Income Tax (Employments) (No. 25) Regulations 1993 (S.I. 1993/726) Income Tax (Employments) (No. 26) Regulations 1993 (S.I. 1993/727) Rules of the Air (Second Amendment) Regulations 1993 (S.I. 1993/728) Derbyshire, Nottinghamshire and South Yorkshire (County and District Boundaries) Order 1993 (S.I.
When the type of snake is unknown, antivenom is often given based on the types known to be in the area. In some areas of the world, getting the right type of antivenom is difficult and this partly contributes to why they sometimes do not work. An additional issue is the cost of these medications. Antivenom has little effect on the area around the bite itself. Supporting the person's breathing is sometimes also required. The number of venomous snakebites that occur each year may be as high as five million. They result in about 2.5 million envenomations and 20,000 to 125,000 deaths. The frequency and severity of bites vary greatly among different parts of the world. They occur most commonly in Africa, Asia, and Latin America, with rural areas more greatly affected. Deaths are relatively rare in Australia, Europe and North America. For example, in the United States, about seven to eight thousand people per year are bitten by venomous snakes (about one in 40 thousand people) and about five people die (about one death per 65 million people).
Sources: en.wikipedia.org
=== Other haematology apparatus === Automatic erythrocyte sedimentation rate (ESR) readers, while not strictly analysers, do preferably have to comply to the 2011-published CLSI (Clinical and Laboratory Standards Institute) "Procedures for the Erythrocyte Sedimentation Rate Test: H02-A5 and to the ICSH (International Council for Standardization in Haematology) published "ICSH review of the measurement of the erythrocyte sedimentation rate", both indicating the only reference method, being Westergren, explicitly indicating the use of diluted blood (with sodium citrate), in 200 mm pipettes, bore 2.55 mm. After 30 or 60 minutes being in a vertical position, with no draughts and vibration or direct sunlight allowed, an optical reader determines how far the red cells have fallen by detecting the level.
1985 Goldenes Ehrenzeichen, Republic of Austria 1994 Austrian Decoration for Science and Art, Republic of Austria 1997 Honorary Member, Slovak Chemical Society 2003 Cross of Merits, State of Tyrol 2004 Cross of Merits, Austria 2007 Cross of Honours in Science and Arts first class, Republic of Austria 2008 Jan-Weber-Medal of the Slovak Pharmaceutical Society 2010 Sitara-e-Qaid-i-Azam (Civil decoration of Pakistan) 2011 Knight Grand Cross (First Class of The Most Exalted Order of the White Elephant with Slash) According to the Theoretical Chemistry Genealogy Project, Bernd Michael Rode is the most successful doctoral thesis supervisor of German-speaking countries in the field of Theoretical Chemistry. Between 1976 and 2011 Prof. Rode has led not less than 70 students to their Ph.D. degree. Due to his close contacts to South-East-Asia many of them come from Asian countries.
=== Controlling properties === The initial nucleation stages of the synthesis process heavily influence the properties of a nanoparticle. Nucleation, for example, is vital to the size of the nanoparticle. A critical radius must be met in the initial stages of solid formation, or the particles will redissolve into the liquid phase. The final shape of a nanoparticle is also controlled by nucleation. Possible final morphologies created by nucleation can include spherical, cubic, needle-like, worm-like, and more particles. Nucleation can be controlled predominately by time and temperature as well as the supersaturation of the liquid phase and the environment of the synthesis overall.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.